## **HHS Public Access**

Author manuscript

Clin Infect Dis. Author manuscript; available in PMC 2017 January 15.

Published in final edited form as:

Clin Infect Dis. 2016 January 15; 62(2): 267–268. doi:10.1093/cid/civ834.

## Reply to Hong-min et al

N. Sarita Shah<sup>1,a</sup>, Courtney M. Yuen<sup>2,3</sup>, Moonseong Heo<sup>4</sup>, Arielle W. Tolman<sup>5</sup>, and Mercedes C. Becerra<sup>2,6</sup>

<sup>1</sup>Division of Global HIV and AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia

<sup>2</sup>Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts

<sup>3</sup>Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts

<sup>4</sup>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York

<sup>5</sup>Department of Sociology, Northwestern University, Evanston, Illinois

<sup>6</sup>Partners In Health, Boston, Massachusetts

## To the Editor

We thank Hong-min et al for their interest in our study [1, 2]. They request clarification of the exclusion criteria of studies with fewer than 5 household contacts. We set this minimum a priori in order to avoid bias from very small studies that are likely to have poor accuracy and precision in measuring the outcomes of interest, namely, prevalence of tuberculosis disease and latent tuberculosis infection among household contacts. Our rationale was to prevent such small studies from having undue influence on estimation of overall prevalence based on random effects models. Although there may be a concern for bias in excluding small studies, this criterion applied to only 2 otherwise eligible studies [3, 4] that reported evaluation of 2 and 3 contacts of index patients with drug-resistant tuberculosis. Hong-min et al also suggest that including studies with a single source case could introduce significant heterogeneity and publication bias. While we agree such studies could introduce heterogeneity, we considered that including them reduces bias because studies from low-burden multidrug-resistant tuberculosis settings could be included without affecting the precision of outcome measures.

A formal evaluation of the quality of the included studies using the suggested scales was not conducted. However, each study was eligible for inclusion only if there were data of

**Disclaimer**. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the US Department of Health and Human Services.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Correspondence: N. Sarita Shah, MD, MPH, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS E-04, Atlanta, GA 30329 (bwg2@cdc.gov).

<sup>&</sup>lt;sup>a</sup>The author was at Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, when the original paper was written.

Shah et al. Page 2

sufficient quality and completeness to measure the outcomes of interest, as noted above, prevalence of tuberculosis disease and latent tuberculosis infection among household contacts. The studies we included in our analysis were predominantly cross-sectional. Hongmin et al suggest use of the Newcastle-Ottawa scale or Downs and Black instrument, which are intended for evaluating case-control or cohort designs. One alternative might have been to devise our own quality index (eg, assigning quality "points" to studies that use a standard evaluation protocol). Such a scale would not be considered a validated tool but, nonetheless, might have helped readers interpret our results.

The issue of heterogeneity was, in part, addressed through use of a random effects model. An analysis of the sources of heterogeneity was beyond the scope of our article. We did, nevertheless, conduct various subgroup analyses and failed to identify a subgroup in which prevalence was not significantly heterogeneous (data not shown). However, we are aware of at least 1 study in which researchers are currently evaluating exactly this question (K Velen, personal communication).

Any systematic review of published literature is inherently subject to publication bias, as unpublished results cannot be systematically searched. The tests suggested by Hong-min et al offer a formal measure of publication bias but are more appropriate for use in meta analyses that measure an "effect," for which null findings (or negative studies) may go unpublished. Tests of publication bias are therefore less relevant for our study where we measured the prevalence of a disease rather than the effect of an intervention. Furthermore, 24% (6/25) of included studies reported zero secondary tuberculosis cases, suggesting that publication bias against null results was not as much of a problem for our study as for treatment studies.

## References

- Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014; 58:381–91. [PubMed: 24065336]
- Hong-min W, Xiao-hong Z, Jing W. Note of the methodological flaws in the paper titled Yield of Contact Investigations in Households of Patients with Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. Clin Infect Dis. 201510.1093/cid/civ832
- 3. Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE Jr. Isoniazid-resistant tuberculosis. A community outbreak and report of rifampin prophylaxis failure. JAMA. 1985; 253:2847–9. [PubMed: 3989958]
- Centers for Disease Control and Prevention. Investigation of a genotype cluster of tuberculosis cases
  —Detroit, Michigan, 2004–2007. MMWR Morb Mortal Wkly Rep. 2009; 58:226–9. [PubMed: 19282814]